Understanding Chinese Pharmacopoeia (ChP) 2020
[Wednesday , 15th Jun 2022]
Understanding Chinese Pharmacopoeia (ChP) 2020
Grace Wang
REACH24H Consulting Group China
If you have any question about this webinar, please contact us:
+86 (0)571 8710 3829

The Pharmacopoeia of the People's Republic of China (Chinese Pharmacopoeia, or ChP) is China's official collection of standards for drug development, production, sale, utilization, supervision, and control.

ChP is updated by the Chinese Pharmacopoeia Commission every five years. The latest version is the ChP 2020, of which the API & excipient standards are listed in BaiPharm Database.

In China, all drugs shall comply with the ChP standards to obtain marketing authorization. Therefore, ChemLinked BaiPharm Portal holds this webinar to help drug applicants understand and meet the ChP standards.


Related Article: China Issues the 2020 Edition of Chinese Pharmacopoeia


1. China National Drug Standard System

2. Introduction of Chinese Pharmacopoeia (ChP) 2020

  • History

  • Complication Procedures

  • Contents

  • Main features

  • Implementation

3. How to Get Access to API & Excipient Standards of ChP 2020

Grace Wang
ChemLinked Regulatory Analyst / Editor
Grace Wang is a regulatory analyst and editor specializing in China's pharmaceutical regulations and market trends. She provides articles and webinars to help overseas pharma companies enter the Chinese market. Her areas of focus include DMF filing, NDA, ANDA, pharmacovigilance, health insurance, and volume-based procurement (VBP).